Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy
Launched by NEMA RESEARCH, INC. · Sep 25, 2006
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
The purpose of this study is to determine the safety and efficacy of Cesamet™ in the symptomatic treatment of pain due to diabetic peripheral neuropathy.
This is a phase IV, multi-center, open label outpatient clinical trial evaluating Cesamet™ treatment for control of pain due diabetic peripheral neuropathy. The study has two phases: a Pretreatment Phase and a Treatment Phase.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with diabetic peripheral neuropathic pain
- • Chronic daily pain present for at least 2 months
- • On stable analgesic regimen for one month
- • Baseline pain score greater than 40mm on a visual analog scale
- Exclusion Criteria:
- • Hypersensitivity to compounds in study drug or similar drugs
- • Pregnant or lactating females
- • Drug or alcohol abuse
- • Unstable medical condition
About Nema Research, Inc.
Nema Research, Inc. is a leading clinical trial sponsor dedicated to advancing medical innovation through rigorous research and development. With a focus on therapeutic areas including oncology, neurology, and rare diseases, the company is committed to conducting high-quality clinical trials that adhere to regulatory standards and ethical guidelines. Nema Research leverages a robust network of experienced investigators and cutting-edge technology to accelerate the drug development process, ensuring the delivery of safe and effective treatment options to patients in need. Through collaboration and a patient-centered approach, Nema Research aims to contribute significantly to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aventura, Florida, United States
Hollywood, Florida, United States
Naples, Florida, United States
West Palm Beach, Florida, United States
Patients applied
Trial Officials
Joseph V Pergolizzi, MD
Principal Investigator
NEMA Research, Inc.
Charlotte Richmond, PhD
Study Director
Nema Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials